Stockscreener 앱 받기
46.58
1.38%
0.825
전일 마감가:
$45.75
열려 있는:
$47.16
하루 거래량:
56,991
Relative Volume:
0.08
시가총액:
$2.93B
수익:
-
순이익/손실:
$-107.85M
주가수익비율:
-13.86
EPS:
-3.36
순현금흐름:
$-106.82M
1주 성능:
-5.35%
1개월 성능:
+13.43%
6개월 성능:
+16.65%
1년 성능:
+242.79%
1일 변동 폭
$46.16
$47.16
1주일 범위
$43.41
$49.36
52주 변동 폭
$12.28
$51.61
베라 테라 Stock (VERA) Company Profile
명칭
Vera Therapeutics Inc
전화
650-770-0077
주소
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
VERA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| VERA | 46.68 | 2.93B | 0 | -107.85M | -106.82M | -3.36 |
| VRTX | 447.41 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.11 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.03 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 250.03 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.69 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
베라 테라 Stock (VERA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-25 | 개시 | Oppenheimer | Outperform |
| 2024-01-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-12-18 | 개시 | Raymond James | Outperform |
| 2023-11-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-16 | 개시 | Guggenheim | Buy |
| 2023-01-04 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-01-04 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2022-07-12 | 개시 | JP Morgan | Overweight |
| 2022-05-02 | 개시 | H.C. Wainwright | Buy |
| 2022-04-19 | 개시 | Wedbush | Outperform |
모두보기
베라 테라 주식(VERA)의 최신 뉴스
GSA Capital Partners LLP Has $535,000 Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet - MSN
Calif. Biotech Firm Vera Taps Veteran Chief Legal Officer - Law360
First Turn Management LLC Increases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - MarketBeat
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer - GlobeNewswire
Vera Therapeutics Appoints Former Kite Pharma Legal Head as Chief Legal Officer | VERA Stock News - StockTitan
(VERA) Proactive Strategies - Stock Traders Daily
COMMODORE CAPITAL LP Adjusts Stake in Vera Therapeutics Inc - GuruFocus.com
Kynam Capital Management, LP Increases Stake in Vera Therapeutics Inc - GuruFocus.com
500: Something went wrong - Investing.com India
Vera Therapeutics stock soars to all-time high of $50.98 - Investing.com
Vera Therapeutics stock soars to all-time high of $50.98 By Investing.com - Investing.com Australia
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year HighHere's What Happened - MarketBeat
FMR LLC Reduces Stake in Vera Therapeutics Inc - GuruFocus.com
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study - The Manila Times
Vera Therapeutics Awards $45.17 Stock Options to New Hires in Growth Push | VERA Stock News - StockTitan
Vera Therapeutics (NASDAQ:VERA) Posts Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
Vera Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewswire
Vera Therapeutics to Present at Two Major Healthcare Investor Conferences | VERA Stock News - StockTitan
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $38.00 - MarketBeat
Vera Therapeutics Advances in Autoimmune Treatment - TipRanks
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Boosts Vera Therapeutics (NASDAQ:VERA) Price Target to $75.00 - MarketBeat
Trading (VERA) With Integrated Risk Controls - Stock Traders Daily
Vera Therapeutics (NASDAQ:VERA) Shares Up 7.3%Here's Why - MarketBeat
Vera Therapeutics announces proposed public offering of class A common stock - MSN
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 - Investing.com India
Vera Therapeutics director Beth Seidenberg sells shares for $720,493 By Investing.com - Investing.com Canada
Vera Therapeutics (NASDAQ:VERA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Vera Therapeutics (NASDAQ:VERA) PT Raised to $64.00 at Guggenheim - Defense World
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - GlobeNewswire
Vera Therapeutics (NASDAQ:VERA) Shares Gap DownHere's Why - MarketBeat
Vera Therapeutics price target raised to $64 from $56 at Guggenheim - Yahoo Finance
SEC Form 424B5 filed by Vera Therapeutics Inc. - Quantisnow
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock - The Manila Times
Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $64.00 - MarketBeat
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years - AOL
Vera Therapeutics (NASDAQ:VERA) Shares Gap UpHere's What Happened - MarketBeat
Vera Therapeutics Shares Climb 14% on Positive Results in Kidney Disease Study - MarketWatch
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Benzinga
Vera reports long-term atacicept data at Kidney Week 2024 - The Pharma Letter
VERAVera Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 - The Manila Times
Vera Therapeutics Announces 96-week eGFR Stabilization in - GlobeNewswire
베라 테라 (VERA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
베라 테라 주식 (VERA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Nov 13 '24 |
Sale |
49.50 |
30,625 |
1,516,037 |
85,942 |
0.42%
0.16%
자본화:
|
볼륨(24시간):